|Bid||51.25 x 100|
|Ask||56.61 x 600|
|Day's Range||56.36 - 57.78|
|52 Week Range||42.62 - 86.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.80|
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like DexCom Inc (NASDAQ:DXCM), with a market cap of US$4.98B, are often out of the spotlight.Read More...
In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent acquisitions—especially its acquisition of St. Jude Medical.
NEW YORK, Feb. 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Valero ...
DexCom, Inc. today announced that it plans to release its fourth quarter and full year 2017 financial results after market close on Tuesday, February 27, 2018. Management will hold a conference call to review the company's fourth quarter and full year 2017 performance starting at 4:30 p.m.
Johnson & Johnson (JNJ) released its 4Q17 and fiscal 2017 results on January 23, 2018. The company reported sales growth across its three business segments: Pharmaceuticals, Medical Devices, and Consumer Businesses. The company’s medical device business contributed ~35% to J&J’s total sales in fiscal 4Q17.
UnitedHealthcare, the market leader in Medicare benefit plans1, and DexCom, Inc., the leader in continuous glucose monitoring for diabetes management, today announced an individualized glucose management pilot program driven by wearable technology to help people with Type 2 diabetes manage their condition in real time.
A recent report claims that the company has been working for months to develop a version of Fitbit for kids. Several unnamed sources spoke about the matter, but didn’t provide details on how the devices would differ from current ones. The idea of developing a version of Fitbit for kids makes sense.
DexCom, Inc. , the leader in continuous glucose monitoring , today reported that it achieved preliminary, unaudited revenue of approximately $218 million for the fourth quarter ended December 31, 2017, an increase of 27% over the fourth quarter of 2016.
Fitbit Inc (NASDAQ:FIT) confirmed that it has made its first investment in a startup, in an effort to beat Apple Inc.’s (NASDAQ:AAPL) Apple Watch. The Fitbit investment is in a company called Sano, which aims to develop a wearable, coin-sized blood sugar monitor for diabetics. FIT stock popped on the news on Friday morning, but is now down 2.5% shortly after the bell Monday morning.
Abbott's FreeStyle Libre continuous glucose monitor received Medicare reimbursement, the company said Thursday.
Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States. The device, FreeStyle Libre Flash, was approved by the U.S. Food and Drug Administration in September. It allows diabetes patients to continuously track blood sugar levels without having to prick their fingers.
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
Standing at the threshold of 2018 it is imperative for the investors to find the means which can dilute the macroeconomic woes and help them gain more.
DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.
NEW YORK, Nov. 28, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DexCom, ...